Profitability
This table compares Graybug Vision and Bio-Path’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Graybug Vision | N/A | -77.61% | -71.34% |
| Bio-Path | N/A | -2,842.40% | -337.48% |
Risk and Volatility
Graybug Vision has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Bio-Path has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500.
Institutional and Insider Ownership
49.9% of Graybug Vision shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 7.9% of Graybug Vision shares are owned by company insiders. Comparatively, 0.7% of Bio-Path shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Graybug Vision | $426.96 million | 0.00 | -$35.60 million | ($24.23) | -0.02 |
| Bio-Path | N/A | N/A | -$16.08 million | ($1.06) | -0.06 |
Bio-Path has lower revenue, but higher earnings than Graybug Vision. Bio-Path is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks.
Summary
Graybug Vision beats Bio-Path on 6 of the 9 factors compared between the two stocks.
About Graybug Vision
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
About Bio-Path
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
